| Field | Specification |
|---|---|
| CAS no. | |
| Applications | |
| Molecular weight | |
| Molecular formula | C21H27ClFN7O |
| Purity | |
| SMILES | |
| Form | Solid |
| Storage | |
| Shipping | |
| Catalog no. (Mfr.) | |
| Main SKU |
Compound Overview
YE6144 is a selective, prototypical inhibitor of interferon regulatory factor 5 (IRF5). It suppresses disease course and is especially effective for remission maintenance in a mouse model of systemic lupus erythematosus (SLE), and can be used in SLE research[1]. It is supplied as an orange to red solid (C21H27ClFN7O, MW 447.94) at 96.47% purity.
Physical & Chemical Properties
| CAS Number | 3065657-02-2 |
|---|---|
| Molecular Formula | C21H27ClFN7O |
| Molecular Weight | 447.94 g/mol |
| Purity | 96.47% |
| Appearance | Solid |
| Color | Orange to red |
| SMILES | CC[C@@H](CNC1=CC2=C(NN=C2/C=C/C3=CC=C(N4CCOCC4)N=N3)C=C1F)N.[H]Cl |
| Signaling Pathway | Immunology/Inflammation |
| Solubility | In Vitro: DMSO: 70 mg/mL (156.27 mM; Requires sonication and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO) |
| Storage | 4°C, sealed storage, away from moisture. In solvent: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). |
| Shipping | Room temperature in continental US; may vary elsewhere. |
Literature Cited
Sources cited in this description and in the In Vitro & In Vivo Data tab. Peer-reviewed publications that used this product are listed under References.
Safety
For Research Use Only. Not for use in diagnostic or therapeutic procedures, and not for human or veterinary use. Handle in accordance with the Safety Data Sheet and your institution's chemical hygiene plan.
In Vitro
| Solvent | Solubility | Notes |
|---|---|---|
| DMSO | 70 mg/mL (156.27 mM) | requires sonication and warming and heat to 60°C; use freshly opened DMSO (absorbed moisture lowers solubility) |
Aliquot the stock solution and store it at -80°C (up to 6 months) or -20°C (up to 1 month); sealed storage, away from moisture; avoid repeated freeze-thaw cycles.
In Vivo
Choose the formulation that suits the animal model and route of administration; percentages are volume ratios of the final working solution. Start from a clear DMSO stock (see In Vitro above), add the co-solvents one at a time in the order listed, mixing after each addition, and prepare the working solution fresh on the day of dosing. If precipitation or phase separation occurs, gentle warming or sonication can help.
Protocol 1
| Composition | 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% saline |
|---|---|
| Result | ≥ 10 mg/mL (22.32 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 10 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (100.0 mg/mL) to 400 μL PEG300; then 50 μL Tween-80; then 450 μL saline to bring the volume to 1 mL. Saline: dissolve 0.9 g sodium chloride in ddH2O and make up to 100 mL. |
Protocol 2
| Composition | 10% DMSO + 90% (20% SBE-β-CD in saline) |
|---|---|
| Result | ≥ 10 mg/mL (22.32 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 10 mg/mL (saturation not determined). For 1 mL of working solution: add 100 μL DMSO stock (100.0 mg/mL) to 900 μL 20% SBE-β-CD in saline. 20% SBE-β-CD in saline: dissolve 2 g SBE-β-CD powder in 10 mL saline until clear (4°C, store up to one week). |
Protocol 3
| Composition | 10% DMSO + 90% Corn Oil |
|---|---|
| Result | ≥ 10 mg/mL (22.32 mM); clear solution |
| How to prepare | Gives a clear solution at ≥ 10 mg/mL (saturation not determined). Use with caution if continuous dosing will exceed two weeks. For 1 mL of working solution: add 100 μL DMSO stock (100.0 mg/mL) to 900 μL corn oil. |
Data provided by the manufacturer.
In Vitro
YE6144 (1 or 3 μM; 30 min) inhibits IRF5 phosphorylation in both human PBMCs and mouse splenocytes[1]. In human HC PBMCs, YE6144 (0-10 μM; 30 min) inhibits type I IFN production, with an IC50 of approximately 0.09 μM[1].
Western Blot Analysis[1]
| Cell Line | Human HC PBMCs and mouse WT splenocytes |
|---|---|
| Concentration | 1 μM (PBMCs) and 3 μM (splenocytes) |
| Incubation Time | 30 min |
| Result | Inhibited the phosphorylation of IRF5. |
RT-PCR[1]
| Cell Line | Mouse WT splenocytes |
|---|---|
| Concentration | 3 μM |
| Incubation Time | 30 min |
| Result | Induction of type I IFN genes, Ifnb1 and Ifna stimulated by TLR7 ligands or TLR9 ligands was remarkably weakened. |
In Vivo
YE6144 (40.0 mg/kg; s.c.; once) suppresses disease progression in mouse systemic lupus erythematosus[1].
| Animal Model | NZB/W F1 mouse model of systemic lupus erythematosus (SLE)[1] |
|---|---|
| Dosage | 40.0 mg/kg |
| Administration | s.c., once |
| Result | Suppressed the exacerbation of autoantibody production. Splenomegaly and renal dysfunction were also suppressed by the treatment after disease onset. |
Data provided by the manufacturer. Numbered citations refer to the Literature Cited list in the product description.
Need this compound in a format that drops straight into your assay? We can tailor formulation, chemistry, and documentation so your results stay consistent across runs and re-orders.
- Format options: solid or pre-dissolved solution (choose solvent), target concentration, aliquots, light/moisture-protected packaging
- Chemistry options: free base/acid vs salt forms, hydrate/solvate preference, stereoisomer control (single enantiomer or racemate), close analogs
- Add-on labels & handles: D/¹³C/¹⁵N isotopes (LC-MS/internal standards), azide/alkyne or other functional handles for conjugation
- QC & documentation: standard COA or enhanced analytical pack (HPLC/LC-MS/NMR), chiral purity, residual solvents, water content (KF), method-specific specs
- Scale & continuity: mg to gram scale, bulk pricing, lot reservation, repeat-order continuity
To quote quickly, tell us: compound name + CAS/structure (SMILES or mol file), intended assay context, solvent preference, salt/stereochemistry requirements, purity/QC level, and the amount (mg–g).
Can’t find the compound you’re looking for?
Send the CAS or structure and your specs. We can help source it, suggest close equivalents, or discuss custom synthesis with the right QC documentation (RUO).
McGill University. 2026.
bioRxiv. 2024 August 19.
